OTCMKTS:RDGL Vivos (RDGL) Stock Price, News & Analysis → At first glance, this chart looks like nonsense… (From The TradingPub) (Ad) Free RDGL Stock Alerts $0.12 +0.01 (+9.20%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$0.10▼$0.1250-Day Range$0.05▼$0.1252-Week Range$0.04▼$0.12Volume1.56 million shsAverage Volume1.14 million shsMarket Capitalization$46.18 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Vivos alerts: Email Address Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" About Vivos Stock (OTCMKTS:RDGL)Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States and internationally. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.Read More RDGL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RDGL Stock News HeadlinesApril 15, 2024 | morningstar.comVivos Inc RDGLApril 11, 2024 | finanznachrichten.deVivos Therapeutics, Inc: Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare ReimbursementApril 25, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 23, 2024 | benzinga.comVivos Stock (OTC:RDGL), Quotes and News SummaryFebruary 23, 2024 | thestreet.comVivos IncFebruary 22, 2024 | investorplace.com3 Stocks to Turn $1,000 Into $1 Million: February 2024January 31, 2024 | theglobeandmail.comSpeculation Tuesday: 2 Call Options and 1 Penny Stock to ConsiderDecember 21, 2023 | msn.comNew Hope In Cancer Battle: FDA Grants Breakthrough Device Status To Vivos Inc.'s RadioGelApril 25, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…December 20, 2023 | finance.yahoo.comRadiogel Precision Radionuclide Therapy Receives FDA Breakthrough Device DesignationDecember 20, 2023 | finance.yahoo.comRadiogel™ Precision Radionuclide Therapy™ Receives FDA Breakthrough Device DesignationAugust 7, 2023 | finance.yahoo.comVivos Inc. Announces Certification of Three New IsoPet® Precision Radionuclide Therapy Regional ClinicsMay 15, 2023 | finance.yahoo.comVivos Inc. (RDGL) Stock Historical Prices & Data - Yahoo FinanceJanuary 11, 2023 | finance.yahoo.comVivos Inc Files a New Patent on Alternate Particles for Precision Radionuclide TherapyJanuary 5, 2023 | reuters.comRDGL.PK - Vivos Inc | Stock Price & Latest News | ReutersJanuary 3, 2023 | finance.yahoo.comVivos Inc Files a New Patent on Precision Radionuclide Therapy Support System EquipmentSeptember 15, 2022 | stockhouse.comVivos Inc Files a New Patent on the Hydrogel Component of IsoPet®/RadioGel(TM)September 14, 2022 | finance.yahoo.comVivos Inc Files a New Patent on the Hydrogel Component of IsoPet®/RadioGel™August 18, 2022 | nz.finance.yahoo.comDua Lipa's LBD Looked Like a Pair of Pants With StrapsAugust 16, 2022 | uk.investing.comGreat Elm Group And 3 Other Stocks Under $5 Insiders Are Aggressively BuyingAugust 16, 2022 | finance.yahoo.comVivos Inc. Announces a New IsoPet® Precision Radionuclide Therapy Regional Clinic for Equine TherapyJuly 15, 2022 | benzinga.comVivos (OTC:RDGL), Analyst Ratings, Price Targets, PredictionsJuly 14, 2022 | benzinga.comVivos (OTC:RDGL), Earnings Estimates, EPS, and RevenueMay 12, 2022 | finance.yahoo.comVivos Inc. Provides Intellectual Property Protection UpdateApril 21, 2022 | apnews.comVivos Inc Implements Multiple Patient IsoPet® Therapy DayFebruary 24, 2022 | finance.yahoo.comVivos Inc. Enhances its Intellectual Property ProtectionJanuary 21, 2022 | nasdaq.comRDGL Real-Time QuotesSee More Headlines Receive RDGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vivos and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today4/24/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorFinance Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolOTCMKTS:RDGL CUSIPN/A CIK1449349 Webwww.radiogel.com Phone(509) 736-4000Fax509-736-4007Employees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,890,000.00 Net Margins-9,524.89% Pretax Margin-14,846.15% Return on EquityN/A Return on Assets-180.12% Debt Debt-to-Equity RatioN/A Current Ratio6.57 Quick Ratio6.57 Sales & Book Value Annual Sales$20,000.00 Price / Sales2,308.92 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-5.94Miscellaneous Outstanding Shares388,870,000Free Float316,930,000Market Cap$46.18 million OptionableNot Optionable Beta1.53 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Michael K. Korenko Ph.D. (Age 78)CEO, President & Director Comp: $266.39kDr. Carlton M. Cadwell D.D.S. (Age 79)Independent Chairman & Secretary Dr. David J. Swanberg M.S. (Age 67)P.E., Chief Technical Manager Dr. Nigel R. Stevenson B.Sc.Ph.D., Chief Science OfficerDr. Fu-Min SuChief Radio Chemist & Radiation Safety OfficerKey Competitors9FNASDAQ:JFUAuxly Cannabis GroupOTCMKTS:CBWTFFirst Resource BancorpOTCMKTS:FRSBMid-Southern BancorpNASDAQ:MSVBLifestore Financial GroupOTCMKTS:LSFGView All Competitors RDGL Stock Analysis - Frequently Asked Questions How have RDGL shares performed in 2024? Vivos' stock was trading at $0.0723 at the beginning of the year. Since then, RDGL stock has increased by 64.2% and is now trading at $0.1188. View the best growth stocks for 2024 here. Are investors shorting Vivos? Vivos saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 104,000 shares, an increase of 303.1% from the March 15th total of 25,800 shares. Based on an average daily trading volume, of 634,500 shares, the days-to-cover ratio is currently 0.2 days. View Vivos' Short Interest. When is Vivos' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our RDGL earnings forecast. How were Vivos' earnings last quarter? Vivos Inc. (OTCMKTS:RDGL) posted its quarterly earnings data on Monday, March, 18th. The company reported ($0.01) earnings per share for the quarter. How do I buy shares of Vivos? Shares of RDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:RDGL) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.